Log In
Print
BCIQ
Print
Print this Print this
 

simtuzumab (GS-6624) (formerly AB0024)

Also known as: GS 6624

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionHumanized mAb against lysyl oxidase-like 2 (LOXL2)
Molecular Target Lysyl oxidase-like 2 (LOXL2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today